Defibrotide treatment and disease progression in patients with IgA nephropathy and impaired renal function at diagnosis

Clinical Drug Investigation

Volumn 13, Issue 4, 1997, Pages 185-191

  Frascà, Giovanni M ^a   Martello, Mauro ^a   Canova, Cristina ^a   Isola, Elisabetta ^a   Vangelista, Alba ^a   Bonomini, Vittorio ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; CREATININE; DEFIBROTIDE; PREDNISOLONE; PROSTACYCLIN; PROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE COURSE; DRUG EFFICACY; FEMALE; FIBRINOLYSIS; HUMAN; HUMAN TISSUE; IMMUNOGLOBULIN A NEPHROPATHY; KIDNEY BLOOD FLOW; KIDNEY DISEASE; KIDNEY FUNCTION; MALE; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROSTAGLANDIN SYNTHESIS; PROTEIN URINE LEVEL; RANDOMIZED CONTROLLED TRIAL;

EID: 0031000122     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/00044011-199713040-00002     Document Type: Article

References (35)

1. D'Amico G. Influence of clinical and histological features on actuarial renal survival in adult patients with idiopathic IgA nephropathy, membranous nephropathy, and membrano-proliferative glomerulonephritis: survey of the recent literature. Am J Kidney Dis 1992; 20: 315-23
2. Fassbinder W, Brunner FP, Brynger HB, et al. Combined report on regular dialysis and transplantation in Europe, 1989. Nephrol Dial Transplant 1991; 6: 34-5
3. Begenschutz, O, Bohle A, Batz C, et al. IgA nephropathy: on the importance of morphological and clinical parameters in the long-term prognosis of 239 patients. Am J Nephrol 1990; 10: 137-47
4. Van Es L. Pathogenesis of IgA nephropathy. Kidney Int 1992; 41: 1720-9
5. Woo KT, Tan YO, Yap KH, et al. Beta-thromboglobulin in mesangial IgA nephritis. Thromb Res 1981; 24: 259-62
6. Lee GSL, Lau YK, Woo KT, et al. Platelet factor 4 in IgA nephritis [letter]. Clin Nephrol 1991; 35: 44
7. Dohi K, Iwano M, Muraguchi A, et al. The prognostic significance of urinary interleukin h in IgA nephropathy. Clin Nephrol 1991; 35: 1-5
8. Coppo R, Amore A, Gianoglio B, et al. Angiotensin II local hyperreactivity in the progression of IgA nephropathy. Am J Kidney Dis 1993; 21: 593-602
9. Gesualdo L, Emancipator SN, Kesselheim C, et al. Glomerular hemodynamics and eicosanoid synthesis in a rat model of IgA nephropathy. Kidney Int 1992; 43: 106-14
10. Coppo R, Roccatello D, Amore A, et al. Effects of a gluten-free diet in primary IgA nephropathy. Clin Nephrol 1990; 33: 72-86
11. Clarkson AR, Seymour AE, Woodroffe AJ, et al. Controlled trial of phenytoin therapy in IgA nephropathy. Clin Nephrol 1980; 13:215-8
12. Kobayashi Y, Fujii K, Hiki Y, et al. Steroid therapy in IgA nephropathy: a retrospective study in heavy proteinuric cases. Nephron 1988; 48: 12-7
13. Frascà GM, Vangelista A, Martella D, et al. Prevention of chronic glomerular uremia in steroid resistant glomerulonephritis. A clinical trial with a new antithrombotic agent. Int J Artif Organs 1990; 13: 421-9
14. Palmer KJ, Goa KL. Defibrotide. A review of pharmacodynamic and pharmacokinetic properties, and therapeutic use in vascular disorders. Drugs 1993; 45: 259-94
15. Lianos EA, Andres GA, Dunn MJ. Glomerular prostaglandin and thromboxane synthesis in rat nephrotoxic serum nephritis. J Clin Invest 1983; 72: 1439-48
16. Stahl RAK, Adler S, Baker PJ, et al. Enhanced glomerular prostaglandin formation in experimental membranous nephropathy. Kidney Int 1987; 31: 1126-31
17. Rahman MA, Emancipator SN, Dunn MJ. Immune complex effects on glomerular eicosanoid production and renal hemodynamics. Kidney Int 1987; 31: 1317-26
18. Cook HT, Cattel V, Smith J, et al. Effect of a thromboxane synthetase inhibitor on eicosanoid synthesis and glomerular injury during acute unilateral glomerulonephritis in the rat. Clin Nephrol 1986; 26: 195-202
19. Purkerson ML, Joist JH, Yates J, et al. Inhibition of thromboxane synthesis ameliorates the progressive kidney disease of rats with subtotal renal ablation. Proc Natl Acad Sci USA 1985; 82: 193-7
20. Yamashita W, Ho Y, Weiss MA, et al. A thromboxane synthetase antagonist ameliorates progressive renal disease of Dahl-S rats. Kidney Int 1988; 33: 77-83
21. Donadio JV, Bergstrahl EJ, Offord KP, et al. A controlled trial of fish oil in IgA nephropathy. N Engl J Med 1994; 331: 1194-9
22. Bennett WM, Walker G, Kincaid-Smith P. Treatment of IgA nephropathy with eicosapentanoic acid (EPA): a two year prospective trial. Clin Nephrol 1989; 31: 128-31
23. Cheng IKP, Chan PCK, Chan MK. The effect of fish oil dietary supplement on the progression of mesangial IgA glomerulonephritis. Nephrol Dial Transplant 1990; 5: 241-6
24. Pettersson EE, Rekola S, Berglund L, et al. Treatment of IgA nephropathy with omega-3 polyunsaturated fatty acids: a prospective, double blind, randomised study. Clin Nephrol 1994; 41: 183-90
25. Donadio JV Jr. Omega-3 polyunsaturated fatty acids: a potential new treatment of immune renal disease. Mayo Clin Proc 1991; 66: 1018-28
26. 3) is formed in human platelets after dietary eicosapentaenoic acid (C20:5ω3). Biochem Biophys Res Commun 1983; 116: 1091-9
27. Sperling Rl, Robin JL, Kylander KA, et al. The effects of N-3 polyunsaturated fatty acids on the generation of platelet-activating factor-acether by human monocytes. J Immunol 1987; 139: 4186-91
28. Stricker RB, Reyes PT, Corash L, et al. A 210 glycoprotein that serves as a platelet Fc receptor. J Clin Invest 1987; 79: 1589-94
29. Wardle EN. Cells and mediators in glomerulonephritis. Nephron 1988; 49: 265-76
30. Camussi G. Potential role of platelet-activating factor in renal pathophysiology. Kidney Int 1986; 29: 469-77
31. Barnes JL, Levine SP, Venkatachalam MA. Binding of platelet factor four (PF 4) to glomerular polyanion. Kidney Int 1984; 25: 759-65
32. Camussi G, Tetta C, Coda R, et al. Platelet-activating factor-induced loss of glomerular anionic charges. Kidney Int 1984; 25: 73-81
33. Abboud HE. Platelet-derived growth factor and mesangial cells. Kidney Int 1992; 41: 581-3
34. Geualdo L, Pinzani M, Floriano JJ, et al. Platelet-derived growth factor expression in mesangial proliferative glomerulonephritis. Lab Invest 1991; 65: 160-7
35. Woo KT, Lee GSL, Lau YK, et al. Effects of triple therapy in IgA nephritis: a follow-up study 5 years later. Clin Nephrol 1991; 36: 60-6